0 CHECKOUT

Insulin Resistance - Pipeline Review, H2 2015

  • ID: 3387889
  • July 2015
  • 64 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AUS Bio Limited
  • Genfit SA
  • GlaxoSmithKline Plc
  • Mertiva AB
  • Novartis AG
  • Prometheon Pharma, LLC
  • MORE

Insulin Resistance - Pipeline Review, H2 2015

Summary

The report ‘Insulin Resistance - Pipeline Review, H2 2015’, provides an overview of the Insulin Resistance’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AUS Bio Limited
  • Genfit SA
  • GlaxoSmithKline Plc
  • Mertiva AB
  • Novartis AG
  • Prometheon Pharma, LLC
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Insulin Resistance Overview
Therapeutics Development
Pipeline Products for Insulin Resistance - Overview
Pipeline Products for Insulin Resistance - Comparative Analysis
Insulin Resistance - Therapeutics under Development by Companies
Insulin Resistance - Therapeutics under Investigation by Universities/Institutes
Insulin Resistance - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Insulin Resistance - Products under Development by Companies
Insulin Resistance - Products under Investigation by Universities/Institutes
Insulin Resistance - Companies Involved in Therapeutics Development
AUS Bio Limited
Genfit SA
GlaxoSmithKline Plc
Hadasit Medical Research Services & Development Ltd
Mertiva AB
Mochida Pharmaceutical Co., Ltd.
Novartis AG
Prometheon Pharma, LLC
Sanofi
Insulin Resistance - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
6860766 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVS-857 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
englerin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MD-960 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-Catalase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide for Obesity and Insulin Resistance - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-088 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SERX-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Hypertension and Insulin Resistance - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Insulin Resistance - Recent Pipeline Updates
Insulin Resistance - Dormant Projects
Insulin Resistance - Product Development Milestones
Featured News & Press Releases
Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Insulin Resistance, H2 2015
Number of Products under Development for Insulin Resistance - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Insulin Resistance - Pipeline by AUS Bio Limited, H2 2015
Insulin Resistance - Pipeline by Genfit SA, H2 2015
Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H2 2015
Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015
Insulin Resistance - Pipeline by Mertiva AB, H2 2015
Insulin Resistance - Pipeline by Mochida Pharmaceutical Co., Ltd., H2 2015
Insulin Resistance - Pipeline by Novartis AG, H2 2015
Insulin Resistance - Pipeline by Prometheon Pharma, LLC, H2 2015
Insulin Resistance - Pipeline by Sanofi, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Insulin Resistance Therapeutics - Recent Pipeline Updates, H2 2015
Insulin Resistance - Dormant Projects, H2 2015

List of Figures
Number of Products under Development for Insulin Resistance, H2 2015
Number of Products under Development for Insulin Resistance - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

AUS Bio Limited
Genfit SA
GlaxoSmithKline Plc
Hadasit Medical Research Services & Development Ltd
Mertiva AB
Mochida Pharmaceutical Co., Ltd.
Novartis AG
Prometheon Pharma, LLC
Sanofi

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.